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A B S T R A C T
Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by immune-mediated muscular
lesions that may be associated with extra-muscular manifestations involving skin, lungs, heart or joints. Four
main groups of IIM can be distinguished: dermatomyositis (DM), overlap myositis including mainly anti-syn-
thetase syndrome (ASS), immune mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM).
Myositis-specific autoantibodies (MSA) are increasingly recognized as valuable tools for diagnosis, classification
and prognosis of IIM. For example, ASS is associated with anti-aminoacyl tRNA synthetase antibodies (anti-Jo-1,
PL-7, PL-12, …), IMNM with anti-SRP and anti-HMGCR; IBM with anti-cytosolic 5’nucleotidase 1A (cN1A), and
DM with anti-Mi-2, anti-MDA-5, anti-TIF-1γ, anti-NXP-2 and anti-SAE. Moreover, anti-MDA-5 is associated with
amyopathic myositis and interstitial lung disease and anti-TIF-1γ and anti-NXP-2 with juvenile DM as well as
malignancy in patients> 40 years. Most MSA have initially been discovered by immunoprecipitation. In routine
laboratories, however, MSA are screened for by indirect immunofluorescence and identified by (automated)
monospecific immunoassays or by multispecific immunoassays (mainly line/dot immunoassays). Validation of
these (multispecific) assays is a challenge as the antibodies are rare and the assays diverse. In this review, we
give an overview of the (clinical) performance characteristics of monospecific assays as well as of multispecific
assays for detection of MSA. Although most assays are clinically useful, there are differences between techniques
and between manufacturers. We discuss that efforts are needed to harmonize and standardize detection of MSA.
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Idiopathic inflammatory myopathies (IIM) are immune-mediated
diseases centered around destruction of muscle tissue due to distinct
pathophysiological mechanisms [1]. Actually, it is currently recognized
that IIM may also present without myositis, with skin, lung, heart or
joint manifestations or in overlap with other systemic autoimmune
rheumatic diseases (SARD). These different entities of IIM each have
their typical set of clinical manifestations, histopathological findings,
and autoantibodies [1–5]. The expanding number of IIM/myositis-
specific autoantibodies (MSA) is a challenge for laboratories specialized
in clinical immunology because detection of these relatively rare anti-
bodies involves a combination of mono- and multi-specific im-
munoassays. The first challenge is to select a test panel of good quality,
the second challenge is to verify this panel for each distinct autoanti-
body, and the third challenge is to incorporate the tests within the
testing algorithm for SARD [6].
Traditionally, there is a special symposium organized by the
European Autoimmunity Standardization Initiative (EASI) at the
biannual International Congress on Autoimmunity [7]. At the recent
11th International Congress on Autoimmunity in Lisbon (May 2018) the
EASI symposium was dedicated to the role of autoantibody detection in
the diagnostic work-up of IIM. Within the clinical spectrum of IIM and
the increasing array of autoantibodies, the challenges of autoantibody
detection have been discussed with a focus on the different approaches
to verify the quality of the immunoassays currently available. This
verification is a requirement for ISO 15189 accreditation, which ap-
pears more difficult to achieve for autoimmune diagnostic laboratories
[8].
The current review first provides an overview of the clinical spec-
trum of IIM, the array of MSA, and the possible role of the indirect
immunofluorescence (IIF) test for the detection of anti-nuclear anti-
bodies (ANA). Next, the approaches that have been used to verify
mono- and multi-specific immunoassays for the detection of MSA will
be summarized. The discussion will focus on issues related to the need
for standardization and harmonization of these immunoassays for ap-
propriate implementation in daily clinical practice.
2. The clinical spectrum of idiopathic inflammatory myopathies
The IIM are a heterogeneous group of diseases, characterized by
muscular immune-mediated lesions that may be associated with sys-
temic inflammation involving other structures, such as joints, skin,
lungs and heart.
The clinical spectrum of IIM covers a wide range of signs and
symptoms and clinical features. Patients can present with symptoms
related to muscle lesions, such as muscle weakness or pain. The extra-
muscular manifestations may develop synchronously with muscular
symptoms or may be the only clinical signs at disease onset and even
during follow-up. Extramuscular manifestations include skin changes
(e.g heliotrope rash, mechanic hands or Raynaud's phenomenon), re-
spiratory complaints (dyspnea on exertion or cough), and articular
signs (arthralgia or arthritis), with or without constitutional symptoms.
Furthermore, some IIM patients have an underlying malignancy.
Most of these clinical features are not specific. In addition, myositis
can be the only manifestation of a muscular specific autoimmune dis-
ease (e.g. immune mediated necrotizing myopathy), constitutive of a
systemic phenotype of IIM (e.g. anti-synthetase syndrome), or a part of
the spectrum of systemic diseases (e.g. systemic sclerosis or mixed
connective tissue disease).
Historically IIM were classified into two categories: dermatomyo-
sitis (DM), defined as myositis with characteristic skin changes, and
polymyositis (PM), defined by proximal muscle weakness, elevated
muscles enzymes, presence of inflammatory alterations on muscle
biopsy and myopathic features on electromyography, without DM skin
rash [9]. To date, based on the muscle pathology, the extramuscular
manifestations and the presence of MSA, it is possible to delineate four
main groups of IIM: DM, overlap myositis including mainly anti-syn-
thetase syndrome (ASS), immune mediated necrotizing myopathy
(IMNM), and inclusion body myositis (IBM) [10–14].
2.1. Subtypes of idiopathic inflammatory myopathies
- Dermatomyositis: this group is hallmarked by a characteristic skin
rash including, Gottron's sign or papules, periungual erythema, V
and shawls sign and liliaceous eyelid edema (heliotrope rash),
whereas the spectrum of muscle involvement ranges from severe
symmetrical proximal weakness to no muscular deficit (clinically
amyopathic DM). Along that line, a third of DM patients has normal
creatine kinase level. The myopathological features are character-
istic, combining by definition a perifascicular atrophy with a vas-
culopathy [12,13]. Nevertheless, DM remains a heterogeneous
group since in addition to musculocutaneous variations among the
DM phenotypes, some patients may present with polyarthritis, se-
vere and rapidly progressive interstitial lung disease (ILD) or ma-
lignancy. These DM subtypes are associated with specific MSA.
- Anti-synthetase syndrome: this subset is clinically characterized
by the triad of myositis, ILD and arthritis, often in a symmetric
polyarticular pattern. This triad can be accompanied with Raynaud's
phenomenon, mechanic's hands and fever. The ASS is linked to the
presence of anti-synthetase antibodies, further referred to as anti-
aminoacyl-tRNA synthetase (anti-ARS) antibodies. As for DM, the
myopathological features are characteristic, with the presence of a
perifascicular necrotizing myositis [15]. Again, there are variations
in ASS phenotype depending on the type of anti-ARS.
- Immune mediated necrotizing myopathy: contrary to DM and
ASS, IMNM is a subgroup of IIM without clinical extra-muscular
auto-immune manifestation [11]. This entity is characterized by a
severe muscle weakness with a sub-acute onset. Muscle biopsy
findings demonstrate characteristic myofibre necrosis with only
minimal inflammation, if any. Patients often present with high
creatine kinase levels resistant to immunosuppressant strategies
[16–18]. Of note, some patients may have a slowly progressive form
mimicking a muscular dystrophy. IMNM diagnosis is based on ser-
ological (presence of MSA) or pathological criteria [11]. Some
IMNM patients have also an increased risk of malignancy and MSA
are crucial to determine this risk [19].
- Inclusion body myositis: IBM has a phenotype limited to the
muscles. One key feature is that it occurs only after the age of 40,
being the most frequent IIM after the age of 50. Contrary to other
IIMs, IBM is characterized by a slowly progressive course, and an
asymmetrical distribution of muscle weakness, involving not only
the proximal but also the distal muscles (mainly quadriceps muscles
and finger flexors). The muscle pathology is also characteristic,
combining muscle inflammation with CD8+ T cells invading non-
necrotic muscle fibers and signs of muscle degeneration (e.g.: pre-
sence of rimmed vacuoles). This subtype of IIM is also unique since
it does not respond to immunosuppressive drugs [20], whereas all
other IIMs do.
Due to the heterogeneity of IIM, their diagnosis and classification is
often challenging. Nevertheless, making a correct diagnosis is essential
for choosing proper treatment (e.g. IMNM and IBM) and estimating
prognosis (e.g. association of malignancy). In the context of the
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complexity of this group of diseases, with involvement of physicians
with different backgrounds, the use of MSA will definitely contribute to
facilitate and refine IIM diagnosis and classification.
3. Spectrum of autoantibodies in relation to the clinical spectrum
and disease criteria
Autoantibodies can nowadays be found in up to 70% of IIM patients
[1]. Since the discovery of anti-Mi-2 antibodies in 1976 > 20 auto-
antibodies have been found in patients with myositis. They are tradi-
tionally divided into MSA and myositis-associated autoantibodies
(MAA). MSA are found exclusively in patients with a clinical diagnosis
of IIM and are generally mutually exclusive. They are present in up to
50% of IIM patients [3]. MSA are associated with specific clinical fea-
tures in the IIM spectrum and are able to identify subsets of patients
with specific phenotypes of skin, muscle and lung disease and malig-
nancy (see Table 1). MAA can also be found in other SARD and they are
frequently present in patients with overlap disease.
3.1. Dermatomyositis-related autoantibodies
The autoantibodies targeting Mi-2, melanoma differentiation asso-
ciated protein 5 (MDA-5), small ubiquitin-like modifier activating en-
zyme (SAE), nuclear matrix protein 2 (NXP-2) and transcription inter-
mediary factor 1γ (TIF-1γ) are associated with classic DM rashes [1].
Other cutaneous involvement includes psoriasis-like lesions and ‘red on
white’ lesions (anti-TIF-1γ) and calcinosis (anti-NXP-2) [21,22]. Muscle
involvement varies from mild to amyopathic forms, as can be the case
in anti-MDA-5, anti-SAE or anti-TIF-1γ, to severe involvement, as in
anti-NXP-2.
Anti-Mi-2 antibodies were the first MSA detected [23] and are as-
sociated with DM (frequency up to 31%) with typical cutaneous lesions
and relatively mild disease [24].
Anti-MDA-5-positive patients typically suffer from clinically amyo-
pathic DM (typical DM rashes but no myositis). Rapidly progressive and
often therapy-resistant and fatal ILD, is the most dreaded complication
[25–27]. The antibodies were first described in an East-Asian popula-
tion, but they are also found in other populations with reports of an
expanded clinical spectrum (e.g. inflammatory arthritis) [28–30].
Anti-TIF-1γ antibodies are found in adult and juvenile DM [31]. The
antibodies are associated with aggressive skin lesions. In adults above
the age of 40, anti-TIF-1γ antibodies are strongly associated with ma-
lignancy (in up to 75% of anti-TIF-1γ positive patients) [32,33].
Anti-NXP-2 antibodies are found in juvenile and adult DM. The
antibodies are associated with severe cutaneous lesions, including cal-
cinosis. An increased prevalence of malignancy in anti-NXP-2 patients
has repeatedly been suggested but a statistically significant association
has been difficult to prove [34].
Characteristic clinical features/association among patients with
anti-SAE antibodies have not yet been identified [35].
3.2. Anti-aminoacyl-tRNA synthetase autoantibodies
The ASS is the most well-known MSA-defined phenotype. It is as-
sociated with anti-ARS autoantibodies. Anti-Jo-1 was the first to be
discovered [36] and is the most frequently encountered anti-ARS. Seven
other anti-ARSs have been recognized: anti-PL7, anti-PL12, anti-EJ,
anti-OJ, anti-Ha, anti-KS and anti-Zo autoantibodies [reviewed in 1].
Presence and severity of the ASS features as well as survival have been
correlated with the anti-ARS autoantibody specificity [37–40]. For ex-
ample, myositis and joint involvement was more common and ILD less
frequent in anti-Jo-1 than in anti-PL7/PL-12 ASS patients [35,36];
Survival was lower in non-anti-Jo-1 than in anti-Jo-1 ASS patients
[38,40]. ILD can be the sole presenting clinical feature. Detection of
MSA is particularly relevant in this group, given the better prognosis of
myositis-related ILD compared to idiopathic pulmonary fibrosis [41].
3.3. Immune-mediated necrotizing myopathy-related autoantibodies
IMNM is associated with antibodies to signal recognition particle
(SRP) and 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) [re-
viewed in [16] and [42]]. The muscle pathology is by definition char-
acterized by a diffuse necrotizing myopathy whereas muscle in-
flammation is only observed in the severe forms [43]. The presence of
anti-SRP is associated with severe symmetric proximal muscle disease,
and can be accompanied by dysphagia and ILD [44]. The presence of
anti-HMGCR is associated with statin use, although this is reported in
only 40–60% of patients [45–47]. Disease course is worse in younger
and juvenile anti-HMGCR positive patients [48,49].
3.4. Inclusion body myositis-related autoantibodies
Anti-cytosolic 5′-nucleotidase 1A autoantibodies (anti-cN1A; pre-
viously referred to as anti-Mup44) are the only known autoantibodies
associated with IBM. Anti-cN1A autoantibodies are present in 30–50%
of IBM patients, but they have also been found in patients with juvenile
DM [50] or other SARD, such as Sjögren's syndrome and systemic lupus
erythematosus [51,52]. A recent study found an increased risk of
mortality in anti-cN1A-positive patients [53].
3.5. Common myositis-associated autoantibodies
Anti-PM/Scl patients classically have an overlap disease of myositis
and systemic sclerosis [54]. Anti-U1RNP patients overlap with mixed
connective tissue disease. Anti-Ro52 co-occurs frequently with anti-Jo-
1 and potentially identifies patients with more severe ILD [55,56].
Additional less-frequent MAA have been described [57].
3.6. Current role of autoantibodies in classification criteria and diagnosis
Autoantibodies were first included in classification criteria by Love
et al. in 1991 [58] and still play a prominent role in a recent classifi-
cation proposal by Senécal et al. in 2017 [57]. The European League
Against Rheumatism (EULAR) and American College of Rheumatology
(ACR) jointly published new classification criteria for adult and juvenile
IIM in 2017 in which they discerned 4 groups (PM, DM, amyopathic DM
and IBM) [13]. Of the 5 examined MSA (anti-Jo-1, anti-Mi-2, anti-SRP,
anti-PL7 and anti-PL12) only the presence of anti-Jo-1 autoantibodies
was retained and assigned the highest number of score points. The lack
of sufficient observations of the other MSA prohibited further analyses
and incorporation and this was perceived a major limitation of the long
awaited new classification criteria [59]. Additional criteria by Mar-
iampillai et al. based on unsupervised analysis and hierarchical cluster
analysis of a cohort of 260 patients revealed that MSA, but not muscle
biopsy findings, were crucial for classification into 4 subgroups (DM,
IMNM, IBM, ASS) [10]. For IMNM, classification and diagnostic criteria
based on clinical features and presence of anti-HMGCR or anti-SRP
without need for muscle biopsy have been proposed, in addition to
pathological criteria [11].
In current clinical practice, MSA already play a key role in diag-
nosis, next to CK levels, electromyography and muscle biopsy. As each
autoantibody is associated with a specific clinical phenotype, as well as
characteristic muscle biopsy findings [60], identification of such an
autoantibody in the near future could obviate the need for an invasive
muscle biopsy, as is already the case for IMNM. The high specificity of
MSA allows adequate differential diagnosis with other non-IIM types of
myopathy (e.g., metabolic, genetic, or toxic myopathy) and between
IIM subgroups. This expanding role demands reliable and practical MSA
assays. Further validation of assays and implementation of autoanti-
body status in upcoming studies are therefore of paramount im-
portance.
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4. The role of ANA in the diagnostic work-up of idiopathic
inflammatory myopathies
Detection of anti-nuclear antibodies (ANA), as detected by an in-
direct immunofluorescence assay (IIFA) on HEp-2 cells, is considered
the most optimal screening assay for autoantibodies in the SARD [61].
Whether this also holds for the IIM is more than questionable for several
reasons. First, in the international recommendations on ANA testing, as
issued by a combined effort of the International Union of Im-
munological Societies (IUIS) and the EASI, it is recognized that the ANA
IIFA is not sufficiently sensitive for the spectrum of MSA, in particular
for the anti-ARS autoantibodies [62]. This has recently been confirmed
in a large dataset obtained in a routine setting [63]. Second, there is no
consensus on whether autoantibodies to cytoplasmic components of the
HEp-2 cells are to be considered as ANA positive [64]. Taking into
account cytoplasmic staining in the HEp-2 IIFA strongly increases the
sensitivity for the ASS [65] and asks for adequate reflex-testing. Third,
in the widely used algorithm for reflex-testing upon a positive ANA
result, often only anti-Jo-1 antibodies are included. Therefore, it has
been advocated that upon clinical suspicion of IIM, the first test of
choice is a multispecific immunoassay for the whole spectrum of MSA
[6,66]. However, these tests still await approval by the US Food and
Drug Administration (FDA) [67]. Furthermore, some autoantibodies,
like anti-HMGCR and anti-cN1A autoantibodies, are not included in the
currently available multispecific immunoassays, they have to be tested
for in monospecific immunoassays as far as warranted by the clinical
manifestations associated with the respective MSA.
Based on the situation described in the previous paragraph, it could
be concluded that there is no role for ANA in the diagnostic work-up of
IIM. However, this is not true. First, several of the MSA do reveal an
HEp-2 IIFA pattern. Therefore, this test can be used for confirmation
upon finding an antigen-specific antibody in the multispecific im-
munoassay. With respect to HEp-2 IIFA patterns, recently a consensus
on nomenclature and description has been published by the
International Consensus on ANA Patterns (ICAP) initiative [68]. The
nuclear patterns associated with the MSA include the fine speckled
patterns (AC-4) for anti-Mi-2 and anti-TIF-1γ autoantibodies, and the
multiple nuclear dots patterns (AC-6) for anti-NXP-2 autoantibodies.
However, many autoantibody specificities can give a fine speckled
nuclear pattern and multiple nuclear dots are not consistently found in
patients with anti-NXP-2 antibodies. With respect to the cytoplasmic
patterns, antibodies to SRP and the ARS, other than Jo-1, reveal the
dense fine speckled patterns (AC-19), while anti-Jo-1 is linked to the
fine speckled pattern (AC-20). Whether the distinct anti-ARS antibodies
really reveal two different patterns is a matter of discussion; this may
also depend on the HEp-2 substrate used for the IIFA. It has been sug-
gested that anti-HMGCR antibodies are associated with a cytoplasmic
staining [69]. However, this is not consistently found and may be
substrate dependent. For some autoantibodies, finding a specific HEp-2
IIFA pattern in conjunction with a positive finding in a multispecific
immunoassay may confer specificity. Such added-value of IIF compared
to dot immunoassay (DIA) has been shown for anti-SRP antibodies [70].
In 60 patients that tested positive by DIA, the presence of the typical
anti-SRP pattern (AC-19) by IIF was strongly associated with IIM: IIM
was present in 30/33 (91%) patients with the typical IIF pattern com-
pared to 6/27 (22%) of patients without the typical IIF pattern [70].
The second reason for including ANA IIF testing in the diagnostic
work-up of IIM is because this disease can occur in overlap with other
SARD, in particular systemic sclerosis. Although the autoantibodies
associated with the overlap syndrome, i.e. antibodies to Ku, PM-Scl and
U1RNP, might be included in some of the IIM multispecific assays, the
clinical manifestations of IIM may not yet be very apparent at the
clinical onset of the disease. For systemic sclerosis, however, the ANA
IIFA is still the best choice as a screening assay [71–74]. Importantly,
the autoantibodies related to the overlap syndrome can also be detected
in the systemic sclerosis multispecific immunoassay and, as such,
should direct the clinician to search for IIM related clinical manifesta-
tions. Again, the HEp-2 IIFA pattern may give a clue to the antigen-
specificity. All three antibodies are associated with nuclear patterns:
anti-Ku with the fine speckled pattern (AC-4), anti-U1RNP with the
large/coarse speckled pattern (AC-5), and anti-PM-Scl with the homo-
geneous nucleolar pattern (AC-8).
Altogether, for some MSA, the HEp-2 IIFA may be of added-value as
a kind of confirmation assay for antigen-specific antibodies identified in
the IIM multispecific immunoassay, or as a screening assay for the
myositis overlap syndromes. Moreover, some IIM patients test positive
by IIF but negative for any of the known MSA, indicating that not all
antibodies have yet been identified/characterized. In addition, some
MSA give a specific staining on tissue substrates. For example, anti-SRP
antibodies give a staining of the gastric chief cells [70] and anti-
HMGCR antibodies give a distinct IIF staining pattern on rat liver sec-
tions (cytoplasmic staining in distinct scattered hepatocytes) [75].
5. Immunoassays for the detection of myositis-specific
autoantibodies
A scala of techniques is available to detect autoantibodies in myo-
sitis. Conventional technologies such as IIF and immunoprecipitation
(IP) use native antigens, are laborious and require a high level of ex-
pertise. In routine diagnostics, enzyme-linked immuno-sorbent assays
(ELISA), and variants thereof, are widely used. These assays use pur-
ified native and recombinant antigens or synthetic peptides, can be
automated, require less expertise and have a better reproducibility.
Conventional technologies employing native antigens generally allow
better detection of antibodies directed against conformational-depen-
dent epitopes as well as epitopes originating from post-translational
modifications. IP is considered the gold standard assay for the detection
of most MSA, with a high sensitivity and specificity.
In recent decades, novel MSA and their clinical associations have
been identified by IP. Yet, different methods for MSA detection have
revealed conflicting results [76]. As more and more commercial assays
are introduced in clinical practice, it is important to compare the per-
formance of the assays to gold standard IP [77]. There are currently
several commercial monospecific and multispecific immunoassays
available to detect MSA. The clinical evaluation of these assays is
summarized in Tables 2 and 3.
5.1. Monospecific immunoassays
Within the spectrum of MSA, anti-Jo-1 is the most widely known
autoantibody. Line immunoassay (LIA) or IP is often used to confirm the
presence of anti-Jo-1, but also ELISA or comparable methods such as
fluoroenzyme immunoassay (FEIA) are commonly used methods to
confirm anti-Jo-1 antibodies. Most manufacturers provide in their kit
inserts information on diagnostic sensitivity and specificity of the assay,
but few have comparative data to IP.
As the presence of anti-Jo-1 has recently been included in the
classification criteria of IIM [13], it is crucial to have reliable methods
for anti-Jo-1 antibody detection. For example, a novel Zenit RA che-
miluminescent immunoassay (CLIA) was found to have a good Kappa
agreement with IP [77]. However, when compared with ELISA, in-
consistent results were still found. More comparative data between
assays are needed [78].
A screening ELISA (MESACUP anti-ARS test, MBL, Nagoya, Japan)
has been developed for the detection of anti-ARS autoantibodies. In
addition to Jo-1, also PL-7, PL-12, EJ, and KS are included as auto-
antigen. This assay is not to be considered a multispecific immunoassay
because the antigen-specificity is not unequivocally determined. This
ELISA kit has a good sensitivity and specificity when compared to IP.
Besides, the assay has also been validated both in patients with IIM as
well as in patients with ILD [79].
Commercial ELISAs are also available for anti-TIF-1γ, anti-Mi-2 and
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anti-MDA-5 for DM, with almost 100% sensitivity and specificity when
compared to IP [80,81]. Anti-Mi-2 can also be detected by FEIA, but no
comparative data to IP is available.
With the introduction of anti-MDA-5 ELISA, patients with rapid
progression of ILD can now be more easily identified. Serial follow-up
of anti-MDA-5 provides prognostic information during the treatment
[82].
The IMNM-specific autoantibodies anti-SRP and anti-HMGCR are
currently part of the diagnostic criteria for IMNM [11]. Anti-SRP anti-
bodies were initially identified by RNA IP. These antibodies were di-
rected against conformational epitopes of SRP, including 7SL RNA and
six polypeptides (molecular weights 72, 68, 54, 19, 14 and 9 kDa) [83].
Recently, an ELISA has been developed and validated for the mea-
surement of anti-SRP antibodies directed against the 54-kDa subunit
(SRP54), which is considered the main antigenic target of anti-SRP
antibodies [84]. The comparison of anti-SRP-54 ELISA and IP showed a
high level of inter method-agreement, with ELISA having both high
specificity (100%) and high sensitivity (88%). However, other studies
indicated that anti-SRP54 antibodies may not be detected by ELISA in
samples containing autoantibodies to 7S RNA of SRP [18,85]. Hence,
there is a risk of false negative results with SRP54-specific im-
munoassays.
Different technologies may be used to detect anti-HMGCR anti-
bodies, including IP, addressable laser-bead immunoassay (ALBIA),
ELISA, and CLIA [45,68,86–88]. In 2012, a novel anti-HMGCR ELISA
exhibited high sensitivity (94.4%) and specificity (99.3%) when com-
pared to IP [45]. Testing of anti-HMGCR positive sera and negative
controls by ALBIA, ELISA, and CLIA in one study [68] and by ELISA and
CLIA in another study [88] demonstrated a very good inter-method
agreement of 100%, with a significant correlation between the levels of
anti-HMGCR antibodies as determined by these methods.
Anti-cN1A autoantibodies were initially detected by immunoblot-
ting from purified skeletal muscle extracts [89]. A novel ELISA is
available for the detection of anti-cN1A IgG autoantibodies with a di-
agnostic specificity of> 96%, and a sensitivity that varied between
35.5% and 39.2% in patients with suspected and definite IBM [90]. As
already mentioned, the high specificity is challenged by the finding that
also patients with systemic lupus erythematosus and Sjögren's syn-
drome may have these autoantibodies. Further commercial assays are
required for combined Ig isotype detection (IgM, IgA, and IgG) that may
increase the diagnostic sensitivity of anti-cN1A autoantibodies.
MAA, like anti-PM/Scl antibodies can also be detected by mono-
specific immunoassays [91–94]. Especially FEIA [91] and ELISA
[92,93] have shown good diagnostic performance compared to con-
ventional methods, including IP.
5.2. Multispecific immunoassays for myositis-specific autoantibodies
In the context of the expanding spectrum of MSA, companies and
laboratories move forward in the direction of multispecific im-
munoassays to safe time, material and labour costs. These multispecific
immunoassays include dot or line immunoassays (DIA/LIA), based on
spotting antigens on nitrocellulose membranes as dot (DIA) or line
(LIA), ALBIA, and solid-phase antigen microarrays. Theoretically, re-
sults for single antibody specificities obtained with multispecific assays
should be comparable to results obtained with conventional techniques,
and in particular with the gold standard IP, which in itself is also a
multispecific technique. In this review, however, we focus on data from
commercially available assays. One might expect even better perfor-
mance characteristics due to increased purity of antigens, selection of
immunodominant antigens as well as more sensitive detection methods.
On the other hand, combining different antigens in one assay may lead
to less optimal assay conditions for each antigen and interference in
read out.
Due to these reasons, validation of multispecific techniques by
comparing results to conventional techniques and with clinically well-
defined myositis patients is a prerequisite for correct interpretation of
results and translation into clinical use and to comply with ISO 15189
guidelines [95]. However, clinical evaluation of IIM multispecific as-
says is challenging due to several reasons.
First, MSA and MAA were originally discovered using conventional
techniques and therefore clinical associations with MSA/MAA were first
described using these techniques [5]. Although IP is often considered
the gold standard, differences between this and newer techniques do
not necessarily reflect superiority of one technique, which makes
comparison more difficult.
Second, if one desires to clinically validate multispecific im-
munoassays, the heterogeneity of the disease should be taken into ac-
count. One approach to tackle this, makes use of samples of clinically
defined patient- and disease control cohorts. Ideally, samples should be
collected at time of diagnosis. While use of clinically defined patients is
superior when antibody frequencies are considerably high, the ap-
proach fails for a disease context with multiple antibodies in very low
frequencies unless the cohort is very large. In addition, patient cohorts
may show a selection bias since different classification criteria were
used. Collaborative studies like the international, multidisciplinary
myositis register, EuroMyositis, currently including>4000 patients
with IIM and involving 23 clinics worldwide might overcome these
problems [96]. Another approach for evaluating multispecific im-
munoassays are studies including consecutive patients with a request
for MAA/MSA testing. Such studies reflect daily diagnostic practice but
often miss a comparison with data obtained with conventional techni-
ques. The studied population is often too small to draw conclusions for
low frequency antibodies and clinical data are more difficult to gather
retrospectively. In addition, patients without a clear diagnosis of IIM at
the time of blood draw might develop IIM later in time. Inclusion of
such patients into the non-IIM control group will negatively influence
the reported specificity. Also, association of MSA with specific clinical
features such as lung disease or malignancy might be underestimated.
Prospective studies that circumvent these problems have not been
performed yet. Ideally, clinical evaluation is combined with comparison
to different existing techniques. Since multispecific assays for the de-
tection of MSA/MAA have only become recently available not many
studies have been published yet. Table 3 summarizes the current re-
levant literature on multispecific assays with details on study design,
assays used, frequencies of MSA/MAA detected and clinical associations
described [99–109].
In conclusion, multispecific DIA/LIA show an increased sensitivity
compared to immunofluorescence-based techniques, especially evident
for anti-ARS autoantibodies [100]. Only two studies describe a com-
parison between the conventional techniques (IP and immunoblot) and
the multispecific LIA [75,98]. In both studies, sensitivity and specificity
(the latter only evaluated in Ghirardello) were higher for the conven-
tional techniques compared to LIA for individual MSA. Two studies
suggest that adjusting cut-off levels might increase specificity of LIA
[102,104]. In general, reported sensitivities and specificities largely
differ. Differences could be explained by differences in the number of
detected antigens, low and varying numbers of patients in the different
IIM subtypes and controls included and also by differences in inclusion
criteria. New EULAR/ACR classification criteria for IIM have recently
been published and should improve comparability of results in future
studies [13]. Since presence of only a single autoantibody (anti-Jo-1) is
included in the classification criteria, future studies should be carefully
designed to avoid a selection bias.
The recent discussion following the study of Vulsteke et al. that
compared three different multispecific assays and revealed considerable
differences in specificity and sensitivity between different DIA/LIA and
for different autoantibodies, nicely demonstrates the current state of
clinical validation of multispecific assays and shows the need for har-
monizing and standardization efforts in multicentre approaches
[105,109,110]. Despite of these shortcomings, use of multispecific as-
says reveals clinically relevant data and facilitates better diagnosis in




Historically, most of the MSA have been identified by IP and clinical
associations were established based on IP. Accordingly, it is important
that mono- and multispecific assays that are used in clinical laboratories
are compared with IP. Such comparisons have been performed for
several autoantibodies and some (mainly monospecific) assays. But, for
the newer technologies (such as the multispecific DIA/LIA) such studies
are scarce and have revealed poor agreement [75,98]. There is also
poor agreement between different DIA and/or LIA [105]. Thus, stan-
dardization of DIA/LIA remains poor with substantial variability be-
tween assays. It should be noted, however, that also IP has dis-
advantages and that considering IP as the gold standard may be
disputed.
HEp-2 IIFA can reveal MSA. However, for several MSA sensitivity is
limited (not 100%). Inversely, the association of HEp-2 IIFA patterns
involved with the presence of MSA is limited. The strongest association
concerns the speckled cytoplasmic patterns with anti-SRP and anti-ARS
antibodies. As HEp-2 IIFA is used to screen for SARD, it is important
that technicians recognize these patterns. Also the nucleolar pattern is
important as it is associated with antibodies found in systemic sclerosis
or scleroderma-overlap syndromes. Multiple nuclear dots can suggest
anti-NXP-2 and the fine speckled nuclear pattern can suggest anti-Mi-2
antibodies, however, these associations are not strong. Anti-HMGCR
gives a distinct pattern on liver tissue and possibly also on HEp-2 cells
[68,74]. Thus, as HEp-2 IIFA is an important technique for SARD
screening, it is important to appreciate its value, but also to recognize
its limitations for MSA detection. Overall, HEp-2 IIFA has a low speci-
ficity and suffers from variability between laboratories.
There is a growing interest in MSA and in daily clinical practice
many clinicians (in rheumatology, neurology, pulmonology or derma-
tology) that take care of patients suspected to have an inflammatory
myopathy request MSA panels (LIA or DIA). In many cases, multi-
specific analysis for MSA is beneficial and allows to diagnose IIM and/
or to provide prognostic information. Therefore, a multispecific ap-
proach for MSA detection is expected to become the standard to eval-
uate patients suspected for IIM. However, as reviewed in this manu-
script, there is variability between assays and efforts are needed to
harmonize/standardize the assays and test interpretation. An important
issue in this respect is to safeguard a high specificity. This is especially
important given the low prevalence of MSA and the clinical relevance.
As previously proposed [102,104,111], a practical way to address this
issue is to use/define several (e.g. 2) cutoff values: a high cutoff that
corresponds to a high specificity and a high likelihood ratio and a
second, lower cutoff to exclude the presence of the antibody. Another,
complementary way to ensure the specificity of a test result obtained by
multispecific immunoassay is to correlate this result with another
monospecific assay or with the HEp-2 IIFA result. The presence of a
corresponding HEp-2 IIFA pattern suggests a specific reaction. This can
be further optimized by including clinical information. Obviously, this
requires good communication between the clinician and the laboratory
specialist: one of the goals of EASI [7].
In conclusion, there is an increasing interest in MSA and MSA are
being included in (clinico-serological) classification criteria
[2,4,11,13]. It is the shared responsibility of the industry, laboratory
professionals and clinicians to offer autoantibody assays that have
clinical value [112]. Multicenter initiatives and (prospective) studies
will be needed to harmonize MSA test results and to further validate
and ensure clinical usefulness of the antibodies [113].
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